Cepheid Joins Tricky POC Space with Group B Strep Test as Third Wave Mulls Move with Japanese Allies | GenomeWeb

This article has been updated from a previous version to eliminate a reference to Cepheid's launch of a Brc/Abl diagnostic, which is not a point-of-care device.

Point-of-care devices with a pharmacogenomic function are finally appearing on the scene.

There are two main areas where there is lot of opportunity for point-of-care molecular diagnostics: infectious disease and adverse drug reactions, and two companies, Cepheid and Third Wave, are charging into the point-of-care space for these two indications, respectively.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.